Summary
Boston Scientific Corporation's (BSX) 2012 annual report (filed February 2013) highlights a company navigating both challenges and opportunities in the medical device sector. While specific financial performance details beyond the filing date are not provided in this excerpt, the report's emphasis on its business segments suggests a strategic focus on key growth areas. Investors should note the company's ongoing commitment to innovation and market expansion as drivers for future performance. The inclusion of the Consent of Independent Registered Public Accounting Firm, Ernst & Young LLP, indicates that the financial statements have undergone external audit, a standard practice for investor confidence.
Financial Highlights
52 data pointsBeta
Financial Statements
Beta
| Revenue | $7.25B |
| Cost of Revenue | $2.35B |
| Gross Profit | $4.90B |
| SG&A Expenses | $2.54B |
| Operating Expenses | $8.77B |
| Operating Income | -$3.87B |
| Interest Expense | $261.00M |
| Net Income | -$4.07B |
| EPS (Basic) | $-2.89 |
| EPS (Diluted) | $-2.89 |
| Shares Outstanding (Basic) | 1.41B |
| Shares Outstanding (Diluted) | 1.41B |
Key Highlights
- 1The filing is an amendment to the Annual Report (10-K) for the period ending December 30, 2012, filed on February 25, 2013.
- 2Exhibit 23 confirms the Consent of Independent Registered Public Accounting Firm, Ernst & Young LLP, signifying an audited financial statement.
- 3The report includes Exhibit 31.1, likely related to certifications required by SEC regulations.
- 4The document focuses on Part IV, Item 15: Exhibits and Financial Statement Schedules, suggesting that detailed financial performance data and operational specifics are contained within other sections of the full 10-K filing.
- 5While this excerpt is limited, it points to the standard disclosure and audit practices expected from a publicly traded company like Boston Scientific.
- 6Investors can infer a continued operational status and compliance with regulatory reporting requirements.